Positive clinical data from London-listed ReNeuron Group’s (AIM:RENE) PISCES II trial has been published in a peer reviewed journal, the company told investors on Monday.
The PISCES II phase 2a clinical trial was an open-label study in patients living with significant disability resulting from ischaemic stroke.
The global cell-based therapeutics company said that data from the study was originally presented by Professor Keith Muir at the American Heart Association International Stroke Conference 2018 in January 2018.
"We are delighted to see the positive results of the PISCES II clinical trial of our CTX cell therapy candidate for stroke disability published in this highly regarded peer-reviewed journal,” said Olav Hellebø, Chief Executive of ReNeuron Group.
Shares in ReNeuron Group were trading 8.62% higher at 157.5p during Monday trading.]
During the PISCES II trial, 23 stable stroke patients were treated with a single dose of 20 million CTX cells a median of seven months post-stroke.
The greatest improvements on the Modified Rankin Scale (mRS), a measure of disability and dependence, were seen in a pre-specified group of fourteen subjects with residual movement of the affected arm.
The statement noted that out of these patients, 38.5% were responders at six months post treatment and 50% were responders at twelve months.
Data from the PISCES II trial has also been published in a paper online in the Journal of Neurology, Neurosurgery, and Psychiatry, the statement added.
Follow News & Updates from ReNeuron Group here: